Yüklüyor......
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
PURPOSE: Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation t...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Clinical Oncology
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3577951/ https://ncbi.nlm.nih.gov/pubmed/23341526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1174 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|